Expanded pharmacogenomic panel enhances safety for patients receiving 5-FU and capecitabine MASON, Ohio, Jan. 5, 2026 /PRNewswire/ — Mira Precision Health todayExpanded pharmacogenomic panel enhances safety for patients receiving 5-FU and capecitabine MASON, Ohio, Jan. 5, 2026 /PRNewswire/ — Mira Precision Health today

Mira Precision Health, Based in Mason, Ohio, Announces U.S. Launch of ToxNav® Advantage™ at the 2026 ASCO® GI Cancers Symposium

Expanded pharmacogenomic panel enhances safety for patients receiving 5-FU and capecitabine

MASON, Ohio, Jan. 5, 2026 /PRNewswire/ — Mira Precision Health today announced the official U.S. launch of ToxNav® Advantage™, a clinically validated pharmacogenomic assay designed to identify cancer patients at increased risk of severe or potentially life-threatening toxicities from fluoropyrimidine-based chemotherapies, including 5-fluorouracil (5-FU) and capecitabine (XELODA®).

This launch comes amid heightened concern regarding fluoropyrimidine safety in certain patient populations. The U.S. Food and Drug Administration recently updated the XELODA® (capecitabine) prescribing information to include a Black Box Warning highlighting the risk of severe, life-threatening, and potentially fatal toxicities in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. This warning underscores the urgent need for proactive identification of genetically at-risk patients prior to initiating treatment with fluoropyrimidines.

Key features of ToxNav® Advantage™ include:

  • Comprehensive analysis of 23 DPYD gene variants
  • Inclusion of DGLUCY and ENOSF1/TYMS variants predictive of fluoropyrimidine-associated cardiotoxicity (CTRCD) and Hand-Foot Syndrome (HFS)
  • Rapid 48-hour turnaround time for clinically actionable results
  • Clear, clinician-friendly reports that support dose optimization, reduced hospitalizations, and lower treatment-related mortality

The launch will be highlighted by a Mira-sponsored Industry Expert Theater (IET) session at the 2026 ASCO® Gastrointestinal Cancers Symposium in San Francisco, CA.

The 45-minute session, titled “From Oxford to the U.S.: The Clinical Utility Evolution of ToxNav® Advantage™ in Preventing 5-FU/Capecitabine Toxicities,” will be presented by Abdul Rahman Jazieh, MD, MPH, Chief Medical Officer of Mira Precision Health. Dr. Jazieh will discuss a real-world case study of fluoropyrimidine-induced cardiovascular toxicity demonstrating the clinical value of variant testing in identifying at-risk patients and informing care decisions.

Professor David Kerr, CBE, MA, MSc, MD, PhD, DSc, FRCP, founder of the original ToxNav® program, internationally recognized oncology researcher, and Chair of Mira Precision Health’s Scientific Advisory Board, will also be onsite throughout ASCO-GI. As the architect of ToxNav’s scientific foundation and a global leader in fluoropyrimidine toxicity research, Professor Kerr will support the U.S. debut of ToxNav® Advantage™ and be available for expert discussions with clinicians, researchers, and industry stakeholders.

ToxNav® Advantage™ builds on more than a decade of peer-reviewed clinical research and real-world implementation of ToxNav® across U.K. and E.U. healthcare systems. The test analyzes 26 clinically relevant gene variants, including 23 DPYD variants aligned with the Association for Molecular Pathology (AMP) 2025 Tier 1 and Tier 2 classifications, along with additional Oxford-validated markers. ToxNav® Advantage™ uniquely extends fluoropyrimidine toxicity risk assessment beyond DPYD deficiency by incorporating genetic variants associated with cancer therapy–related cardiac dysfunction (CTRCD)—a potentially life-threatening complication—and Hand-Foot Syndrome (HFS), a frequent cause of treatment modification or discontinuation in patients receiving fluoropyrimidines.

“We developed ToxNav® to identify patients with a high likelihood of severe toxicity from 5-FU and capecitabine—two of the most widely prescribed cancer therapies worldwide,” said Professor Kerr. “Through our collaboration with Mira Precision Health, ToxNav® has been optimized for the U.S. market, delivering greater clinical utility and rapid turnaround times that can meaningfully improve patient outcomes.”

“ToxNav® Advantage™ provides oncologists with fast, actionable insights to help prevent life-threatening toxicities before treatment begins,” said Dr. Jazieh. “Our mission is to enable precision-driven care that protects patients across every stage of therapy.”

“As a long-time partner of Mira and strong advocate for life science advancement, we’re excited to see this partnership with Oxford bring life-changing technology to the U.S.,” said Michele Blair, Director of Economic Development for the City of Mason. “We’re leaning in to our ‘Mason Living Lab’ platform, which engages city residents and employees as participants to advance new technology. This program differentiates Mason’s position in the Midwestern ecosystem and accelerates science discovery.”

About Mira Precision Health

Mira Precision Health is a CLIA-certified, high-complexity clinical laboratory headquartered in Mason, Ohio, specializing in precision medicine diagnostics. Through its advanced pharmacogenomic and oncology testing solutions, Mira empowers clinicians nationwide to deliver safer, more personalized cancer care.

About the City of Mason, Ohio

The City of Mason, Ohio, is an established hub for biohealth and biotech life science companies, with focus areas in cardiology, mental health and precision medicine. Mason was one of the first cities in Ohio designated a Premier Life Science Ready Community in 2025 by the Ohio Life Sciences Association for its infrastructure readiness, dedicated support systems, accessible real estate and high-quality resources that make it attractive to life science development. For more information about the City of Mason, visit www.whymason.com or www.imaginemason.org.

For media inquiries, please contact:
Lori Borchers
Vice President, Sales and Marketing
Mira Precision Health
Email: [email protected]
Website: https://www.miraprecision.com/toxnav/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mira-precision-health-based-in-mason-ohio-announces-us-launch-of-toxnav-advantage-at-the-2026-asco-gi-cancers-symposium-302652722.html

SOURCE City of Mason

Market Opportunity
Mira Logo
Mira Price(MIRA)
$0.1209
$0.1209$0.1209
-1.22%
USD
Mira (MIRA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

REX Shares’ Solana staking ETF sees $10M inflows, AUM tops $289M for first time

REX Shares’ Solana staking ETF sees $10M inflows, AUM tops $289M for first time

The post REX Shares’ Solana staking ETF sees $10M inflows, AUM tops $289M for first time appeared on BitcoinEthereumNews.com. Key Takeaways REX Shares’ Solana staking ETF saw $10 million in inflows in one day. Total inflows over the past three days amount to $23 million. REX Shares’ Solana staking ETF recorded $10 million in inflows yesterday, bringing total additions to $23 million over the past three days. The fund’s assets under management climbed above $289.0 million for the first time. The SSK ETF is the first U.S. exchange-traded fund focused on Solana staking. Source: https://cryptobriefing.com/rex-shares-solana-staking-etf-aum-289m/
Share
BitcoinEthereumNews2025/09/18 02:34
Why Everyone Is Talking About Saga, Cosmos, and Mars Protocol

Why Everyone Is Talking About Saga, Cosmos, and Mars Protocol

The post Why Everyone Is Talking About Saga, Cosmos, and Mars Protocol appeared on BitcoinEthereumNews.com. Layer-1 blockchain protocol Saga has faced a severe
Share
BitcoinEthereumNews2026/01/22 17:01
CME Group to Launch Solana and XRP Futures Options

CME Group to Launch Solana and XRP Futures Options

The post CME Group to Launch Solana and XRP Futures Options appeared on BitcoinEthereumNews.com. An announcement was made by CME Group, the largest derivatives exchanger worldwide, revealed that it would introduce options for Solana and XRP futures. It is the latest addition to CME crypto derivatives as institutions and retail investors increase their demand for Solana and XRP. CME Expands Crypto Offerings With Solana and XRP Options Launch According to a press release, the launch is scheduled for October 13, 2025, pending regulatory approval. The new products will allow traders to access options on Solana, Micro Solana, XRP, and Micro XRP futures. Expiries will be offered on business days on a monthly, and quarterly basis to provide more flexibility to market players. CME Group said the contracts are designed to meet demand from institutions, hedge funds, and active retail traders. According to Giovanni Vicioso, the launch reflects high liquidity in Solana and XRP futures. Vicioso is the Global Head of Cryptocurrency Products for the CME Group. He noted that the new contracts will provide additional tools for risk management and exposure strategies. Recently, CME XRP futures registered record open interest amid ETF approval optimism, reinforcing confidence in contract demand. Cumberland, one of the leading liquidity providers, welcomed the development and said it highlights the shift beyond Bitcoin and Ethereum. FalconX, another trading firm, added that rising digital asset treasuries are increasing the need for hedging tools on alternative tokens like Solana and XRP. High Record Trading Volumes Demand Solana and XRP Futures Solana futures and XRP continue to gain popularity since their launch earlier this year. According to CME official records, many have bought and sold more than 540,000 Solana futures contracts since March. A value that amounts to over $22 billion dollars. Solana contracts hit a record 9,000 contracts in August, worth $437 million. Open interest also set a record at 12,500 contracts.…
Share
BitcoinEthereumNews2025/09/18 01:39